Next-Generation Bispecific Nanobody Targeting CD274 and RNF128 for Colorectal Cancer Therapy
VHH-P212 is a humanized nanobody-based bispecific chimera designed to target both CD274 molecule (CD274) and ring finger protein 128 (RNF128). Currently in the Biological Testing stage, VHH-P212 is positioned as an innovative therapeutic candidate for colorectal cancer. This unique program harnesses state-of-the-art nanobody engineering to combine the inhibition of two critical immune regulatory checkpoints, offering a novel approach for enhancing anti-tumor immunity. By simultaneously engaging CD274 molecule (CD274) and ring finger protein 128 (RNF128), VHH-P212 has the potential to address key mechanisms of immune evasion in colorectal cancer and set new standards in cancer immunotherapy.
| Candidate | VHH-P212 |
| Target | CD274 molecule (CD274) ring finger protein 128 (RNF128) |
| Modality | humanized bispecific VHH |
| Indication | Colorectal Cancer |
Licensing Opportunity
VHH-P212 is available for licensing and collaborative development. We welcome inquiries from partners interested in advancing this innovative bispecific nanobody program for colorectal cancer and exploring further immunotherapy applications.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P212 |
Modality
VHH-P212 features a bispecific surface removal targeting chimera, utilizing nanobody architecture with single-domain antibody fragments. Nanobodies are markedly smaller and more stable than conventional antibodies, enabling superior tumor penetration and tissue distribution—critical properties for treating solid tumors such as colorectal cancer. The bispecific design allows for the simultaneous and precise targeting of two distinct immunomodulatory molecules, enhancing the likelihood of overcoming tumor-induced immune suppression. Its modular structure supports high affinity and specificity, while also providing flexibility for future engineering, such as conjugation with cytotoxic agents or incorporation into multi-specific formats.
Target
CD274 and RNF128 are central targets in tumor immune modulation. CD274, an immune checkpoint protein frequently overexpressed on tumor cells and tumor-infiltrating immune cells, interacts with the PD-1 receptor to downregulate immune responses, assisting colorectal cancer cells in evading immunosurveillance. RNF128, an E3 ubiquitin-protein ligase, regulates T cell activation and is found on activated T cells in the tumor microenvironment. By targeting both CD274 and RNF128, VHH-P212 aims to block redundant immunosuppressive pathways, restore T cell function, and amplify anti-tumor immunity. The strategic dual targeting of CD274 and RNF128 strengthens the therapeutic rationale and enhances the potential clinical impact in colorectal cancer treatment.
Mechanism of Action
VHH-P212 operates as a dual immune checkpoint inhibitor that binds and blocks both CD274 and RNF128, disrupting key mechanisms that suppress anti-tumor immune responses. By inhibiting CD274, VHH-P212 prevents the engagement of PD-1 on T cells, thereby enhancing T cell activation and effector function. Concurrently, targeting RNF128 interrupts its immunoregulatory activities, further promoting T cell responsiveness within the tumor microenvironment. This synergistic action seeks to overcome immune exhaustion and resistance to single-agent checkpoint blockade. The nanobody platform underlying VHH-P212 also offers significant opportunities for further development, including linkage to cytotoxic payloads or integration within advanced bispecific or multispecific immunotherapies.
Colorectal Cancer
Colorectal cancer is among the most prevalent malignancies globally, representing a major cause of cancer-related morbidity and mortality. With rising incidence in both developed and developing regions, colorectal cancer frequently presents at an advanced stage, highlighting the critical need for improved therapies. Current treatment strategies encompass surgery, chemotherapy, radiotherapy, and targeted biological therapies; however, challenges persist, especially in the treatment of metastatic or recurrent disease. Limitations such as resistance to standard therapies, suboptimal responses to immunotherapy, and significant side effects underscore unmet clinical needs. VHH-P212, with its unique bispecific nanobody format directed at CD274 and RNF128, represents a promising therapeutic avenue. By targeting multiple immune checkpoints, VHH-P212 holds the potential to enhance anti-tumor immunity, address resistance mechanisms, and provide new hope for patients with colorectal cancer.